Background: Topical corticosteroids were first introduced for use in 1951. Since then uncontrolled use (abuse) has caused many different reactions resembling rosacea - steroid dermatitis or iatrosacea. Multiple pathways including rebound vasodilatation and proinflammatory cytokine release have been proposed as the mechanism for such reactions.
Aim: The aim was to study the adverse effects of topical steroid abuse and the response to various treatment modalities.
Materials And Methods: Two hundred patients with a history of topical steroid use on face for more than 1 month were studied clinically and various treatments tried.
Results: The duration of topical corticosteroid use varied from 1 month to 20 years with an average of 19.76 months. Majority of patients were using potent (class II) topical steroids for trivial facial dermatoses. The common adverse effects were erythema, telangiectasia, xerosis, hyperpigmentation, photosensitivity, and rebound phenomenon. No significant change in laboratory investigations was seen.
Conclusion: A combination of oral antibiotics and topical tacrolimus is the treatment of choice for steroid-induced rosacea.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3088930 | PMC |
| http://dx.doi.org/10.4103/0019-5154.77547 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Descriptive Study of Patients Presenting With Topical Steroid Damaged/Dependent Face (TSDF) to a Tertiary Care Center in Northern India.
Cureus
December 2024
Dermatology and Venereology, Srirama Chandra Bhanja (SCB) Medical College and Hospital, Cuttack, IND.
Introduction Topical steroid damaged/dependent face (TSDF) is defined as the semi-permanent or permanent damage to the skin of the face precipitated by the irrational, indiscriminate, or prolonged use of topical corticosteroids (TCs), resulting in various cutaneous signs and symptoms and psychological dependence on the drug. The objective was to determine the clinical spectrum of TSDF. Methods This was an observational cross-sectional study conducted between May 2021 and April 2022, comprising 100 consecutive patients of TC-induced facial dermatoses who visited the skin and venereal disease OPD of a tertiary care hospital in northern India.
View Article and Find Full Text PDFOff-Label Uses of Abrocitinib: Review of Emerging Therapeutic Applications beyond Atopic Dermatitis.
Life (Basel)
September 2024
Department of Otorhinolaryngology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Article Synopsis
- Abrocitinib is a JAK1 inhibitor mainly approved for treating moderate-to-severe atopic dermatitis in those 12 and older, but this review explores its off-label uses.
- Researchers found 37 studies using Abrocitinib for conditions beyond atopic dermatitis, with common cases including vitiligo, prurigo nodularis, and hand eczema, each having 12 reported instances.
- All but one of the 103 patients studied experienced favorable outcomes with Abrocitinib, highlighting its potential for treating multiple skin conditions.
JAK1 inhibitor abrocitinib for the treatment of steroid-induced rosacea: case series.
Front Med (Lausanne)
September 2023
Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Background: Steroid-induced rosacea is a severe withdrawal reaction which can occur after the frequent and excessive topical use of steroids on the face. The Janus kinase (JAK)-signal transducers and activators of transcription signaling pathway is involved in many biological processes and may play a role in the development of steroid-induced rosacea.
Objective: To observe the efficacy and safety of the JAK1 inhibitor abrocitinib in the treatment of steroid-induced rosacea.
Tofacitinib for the Treatment of Steroid-Induced Rosacea.
Clin Cosmet Investig Dermatol
November 2022
Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.
Purpose: Conventional treatment suffers from a dilemma of poor efficacy. The clinical use of Janus kinase (JAK) inhibitors in the treatment of steroid-induced rosacea has rarely been explored.
Patients And Methods: We present a case of steroid-induced rosacea successfully treated with JAK inhibitor tofacitinib, with no adverse effects.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!